Ellington Management Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Ellington Management Group’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-25,300	Closed	-$329K	–	928
2018 Q1	$329K	Buy	+25,300	New	+$377K	0.02%	556
2017 Q1	–	Sell	-11,600	Closed	-$179K	–	916
2016 Q4	$179K	Buy	+11,600	New	+$151K	0.03%	460

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

APCM

Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ellington Management Group's PRTK Position: Q2 2018 in Review

Ellington Management Group sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2018, closing a stake of 25,300 shares — an estimated $329K sold.

Ellington Management Group first reported a position in PRTK in Q4 2016 and held it in 2 quarters. The position peaked at $329K in Q1 2018. 110 funds tracked by Wall St. Rank hold PRTK as of Q2 2018.

Ellington Management Group reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Ellington Management Group sold 25,300 Paratek Pharmaceuticals, Inc. shares in Q2 2018, an estimated $329K.
Ellington Management Group first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2016 and held it in 2 quarters.
Ellington Management Group's Paratek Pharmaceuticals, Inc. position peaked at $329K in Q1 2018.
110 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2018.

Based on Ellington Management Group's 13F filing for Q2 2018, filed 14 Aug 2018.